mar feb jan dec nov oct sep i bit behind listing relevant fda update info i get date zyprexa olanzapine labeling change label revised state rare postmarketing reports hepatitis received rare cases cholestatic mixed liver injury also reported postmarketing period pdf bifeprunox schizophrenia phase iii results released showing patients better placebo months hard beat placebo also reported weight lipid profile reductions new drug application submitted fda october invega iloperidone results results interesting looked efficacy side effects data stratified whether one particular pharmacogenetic genotype identify genotype i suspect something like drd dat far however yet see promise pharmacogenetic test one would perform prior prescribing drug really work test free results available promptly melt mouth methadone roxane got dissolvable mg methadone approved invega iloperidone approved active metabolite risperdal risperidone similar atypical antipsychotic label detailed review